Is adjunctive treatment with medication of liver-soothing-oriented method beneficial for depression after cerebrovascular accident?: A PRISMA-compliant meta-analysis. Issue 44 (November 2016)

• Record Type: Journal Article
• Authors: Zeng, Ling-Feng; Liang, Wei-Xiong; Liu, Jia-Ci; Chen, Xiao-Yan; Du, Wen-Yi; Li, Zi-Ping; Wang, Qi; Cao, Ye; Wang, Lu; Meng, Chang-Rong; Wang, Ke-Zhu; Wang, Ning-Sheng
• Editors: Fornaro., Michele
• Is Part Of: Medicine. Volume 95:Issue 44(2016)
• Page Start: e5208
• Publication Date: 2016-11
• Subjects: adjunctive treatment -- DCVA -- inflammatory cytokines -- meta-analysis -- MLSM -- systematic review; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000005208
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: Adjunctive treatment with medication of liver-soothing-oriented method (MLSM) is one of the most commonly used approaches for subjects with depression after cerebrovascular accident (DCVA) in China. The purpose of this meta-analysis was to evaluate the outcome of MLSM treatment in subjects with DCVA using relevant published literature. Methods: The PubMed, Cochrane Library, Embase, Chinese databases of China National Knowledge Infrastructure, WanFang, Sinomed, and VIP were used to collect all publications until March 2016. Randomized controlled trials comparing treatments with and without MLSM for subjects with DCVA were included. The quality of each publication was assessed based on the recent Handbook (5.1 version) for Cochrane Reviewers. Cochrane Collaboration's software RevMan 5.3 software was applied for data analysis. Results: Thirty studies, including 2599 cases, were identified and collected. Adjunctive treatment with MLSM noticeably enhanced total effective rates (odds ratio 3.76; 95% confidence interval [CI] 2.92–4.85, I 2 = 0%, P = 0.96) in comparison to non-MLSM conventional pharmacotherapy. Compared to non-MLSM treatment, the changes of Hamilton Depression Scale in adjunctive treatment with MLSM, respectively, decreased and showed beneficial effects after 3 weeks (weighted mean difference [WMD] −4.83; 95% CI −6.82 to −2.83; I 2 = 86%, P < 0.001), 4 weeks (WMD −4.20; 95% CI −5.06 to −3.33; I 2 = 78%, P < 0.001), 6 weeks (WMD −3.36; 95% CI −4.05 to −2.68; I 2 = 54%, P = 0.02), 8 weeks (WMD −4.83; 95% CI −5.62 to −4.04; I 2 = 73%, P < 0.001), and 12 weeks (WMD −2.88; 95% CI −4.09 to −1.67; I 2 = 58%, P = 0.09). As for changes in inflammatory cytokine levels, adjunctive treatment with MLSM was associated with a significant decrease in tumor necrosis factor-α, IL-6, and interleukin-1β levels in comparison to non-MLSM treatment. Moreover, there were positive effects on score changes for National Institute of Health Stroke Scale, activities of daily living, Hamilton Anxiety Scale, Modified Edinburgh Scandinavian Stroke Scale, and Self-Rating Anxiety Scale. No serious adverse events were reported. Conclusion: MLSM appears to improve symptoms of depressive disorders, enhance immediate responses, and the quality of life in subjects with DCVA. The positive action of MLSM might be potentially connected with its immunoregulating effects. More prospective trials with strict design and larger sample sizes are warranted to clarify its effectiveness and safety.